OmniSonics, Boston work on stroke tech together
This article was originally published in Clinica
Executive Summary
Vascular disease firm OmniSonics Medical Technologies (Wilmington, Massachusetts) is set to jointly develop its OmniWave technology alongside Boston Scientific for an application in the treatment of acute ischaemic stroke. The OmniWave product is designed to deliver low-power ultrasonic energy to remove a blood clot. Funding of the project, based on the achievement of certain development milestones, will come from Boston, which also has the option to acquire the resulting technology and the exclusive rights to the intellectual property covering the treatment of acute stroke. Other financial details of the licensing and development agreement were not disclosed.
You may also be interested in...
Alere aided by professional diagnostics sales in fourth quarter
Alere’s professional diagnostics business helped the firm record overall revenue growth in the fourth quarter of 2010, offsetting a fall in influenza-based sales in North America.
Integra and Stout to work on expandable interbody device
Integra LifeSciences has gained exclusive worldwide rights from Stout Medical to develop and commercialise an expandable interbody fusion device.
Gen-Probe eyes portfolio expansion to help boost molecular diagnostics credentials
Gen-Probe recently launched its Panther automated molecular diagnostics system in Europe with the aim of bringing another dimension to its product portfolio. Joseph Harvey met the firm’s CEO, Carl Hull, at the launch of the product in Frankfurt to find how high the firm has set its sights in the molecular diagnostics sector and how it is going to achieve its goals